On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...

Turner, a seasoned biotechnology executive, was formerly CEO of Carmot Therapeutics, which was acquired by Roche in 2024 for ...

Hoffmann-La Roche Limited (Roche Canada) is pleased to announce, with support from the Government of Ontario through its ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

Privately-held Flare Therapeutics, a US biotech targeting transcription factors to discover precision medicines for oncology ...

this is one step towards our continued investment and commitment to the life sciences sector in Ontario, our local economy and in healthcare for all Canadians and patients around the world,” said ...

Papadakis covers the Healthcare sector, focusing on stocks such as Sandoz Group Ltd, Zealand Pharma, and BioNTech SE. Roche Holding AG has an analyst consensus of Hold, with a price target consensus ...

Upholding the patent rights of Swiss pharmaceutical giant F-Hoffmann-La Roche AG, the Delhi High Court has once again ...

CPCT chips in financial assistance to 50 children for lifelong access to free Roche drug for SMA treatment: Our Bureau, Bengaluru Friday, November 15, 2024, 11:45 Hrs [IST] Care a ...

Roche Holding AG is extremely optimistic that its latest experimental Alzheimer’s drug will deliver a benefit for patients, Chief Executive Officer Thomas Schinecker said, despite a track record of ...